Last reviewed · How we verify
6MPfixed
6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and suppresses immune cell proliferation.
6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and suppresses immune cell proliferation. Used for Acute lymphoblastic leukemia (ALL), Inflammatory bowel disease (Crohn's disease, ulcerative colitis).
At a glance
| Generic name | 6MPfixed |
|---|---|
| Also known as | PuriNethol, Puri-Nethol (6-mercaptopurine) |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Purine analog, antimetabolite |
| Target | Purine metabolism pathway (HGPRT, TPMT) |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
6MP is converted intracellularly to active metabolites that interfere with purine metabolism, reducing the synthesis of DNA and RNA. This leads to decreased proliferation of lymphocytes and other rapidly dividing cells, making it effective as both an immunosuppressant and antileukemic agent. The 'fixed' designation likely refers to a fixed-dose formulation.
Approved indications
- Acute lymphoblastic leukemia (ALL)
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
Common side effects
- Myelosuppression (leukopenia, thrombocytopenia)
- Hepatotoxicity
- Nausea and vomiting
- Increased infection risk
Key clinical trials
- ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6MPfixed CI brief — competitive landscape report
- 6MPfixed updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI